A post by @FirstSquawk on X.

Novo Nordisk’s CEO said the company is still succeeding in Canada despite losing exclusivity for semaglutide, the active ingredient in its blockbuster diabetes and obesity drugs. The remark signals that the Danish drugmaker sees competitive pressure in the Canadian market as manageable rather than a major setback. Semaglutide underpins key Novo products, making exclusivity losses a closely watched risk for its pricing and market share. Investors will look for further detail on Canadian volumes, pricing and generic or rival penetration in upcoming disclosures.